text.skipToContent text.skipToNavigation

PyroMark Q24 MDx

For IVD-validated mutation and methylation analysis using Pyrosequencing technology
  • Compliant with EU IVD Directive 98/79/EC
  • Reliable quantification of allele representation and methylation status
  • Sequence information enables discovery of rare mutations
  • More than one assay can be completed in a single run
  • 1–24 samples can be analyzed in as little as 15 minutes

The PyroMark Q24 MDx uses proven Pyrosequencing technology for real-time, sequence-based detection and quantification for in vitro diagnostic use in Europe. This innovative platform is highly suited for genotyping mutations, evaluating disease-related DNA methylation patterns, validating biomarkers, and other diagnostic-related assays.

The PyroMark Q24 MDx is intended for in vitro diagnostic use.



Features
Specifications
Altitude Up to 2000 m (6500 ft)
Applications Methylation analysis, allele quantification, genotyping, sequence analysis
CE/FDA/IVD compatible In Europe
Chemical resistance pH 4 to pH 9, common detergents, 0.5 M sodium hydroxide, ethanol
Connections One USB port (2.0)
Humidity Relative humidity of 20–90% (noncondensing)
Instrument dimensions 420 x 390 x 525 mm (16.5 x 15.4 x 20.7 in.)
Kits designed for this instrument IVD-labeled therascreen Kits
Operating temperature 15–32°C (59–90°F)
Overvoltage category II
Place of operation For indoor use only
Pollution level 2
Power 100–240 V AC, 47–63 Hz, 1.1–0.45 A (grounded). From external power supply to instrument: 12 VDC and 24 VDC nominal
Process temperature 28°C (82.4°F) ± 1°C
Process time Depends on the number of nucleotide dispensations (20 dispensations take 24 minutes)
Samples per run (throughput) 1–24
Software PyroMark Q24 MDx Software 2.0
Technology Pyrosequencing
Weight 27.5 kg (60.6 lb)